Au­rinia eye drug falls short in im­prov­ing tol­er­a­bil­i­ty ver­sus Resta­sis, but beats on ef­fi­ca­cy

Al­ler­gan’s best-sell­ing dry eye drug Resta­sis was de­vel­oped af­ter the im­muno­sup­pres­sant was orig­i­nal­ly shown to en­hance tear pro­duc­tion in dogs. Sim­i­lar­ly, Cana­da’s Au­rinia Phar­ma $AUPH found its ex­per­i­men­tal treat­ment was do­ing well in ca­nine stud­ies, prompt­ing their eval­u­a­tion of the drug — vo­closporin opthalmic so­lu­tion (VOS) — in hu­mans. And now in a Phase II study com­par­ing VOS to Resta­sis, VOS failed the pri­ma­ry end­point of beat­ing the block­buster drug’s tol­er­a­bil­i­ty score, but did demon­strate a sta­tis­ti­cal­ly sig­nif­i­cant im­prove­ment on sec­ondary end­points eval­u­at­ing ef­fi­ca­cy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER